Cytori Issued U.S. Patent for Cell-Enriched Fat Grafting
New Patent Protects Key Cytori Market
"Today's announcement broadens our current expansive patent portfolio covering adiposederived cell therapies. The patent covers many significant applications for stem and regenerative cellenriched fat grafting, allowing us to freely develop future generation therapeutics and pursue solutions for patients with unmet medical needs in tissue damage indications, including breast reconstruction," said Christopher J. Calhoun, CEO of Cytori Therapeutics.
Within the Cytori family of products, the Company markets the Celution(R) 800/CRS System that creates adipose tissuederived stem and regenerative cellenriched autologous fat grafts, in the EU and elsewhere throughout the world. The '684 patent is designed to protect the Celution(R) 800/CRS System, as well as future generations of the device, when approved for marketing and sale in the U.S.
The '684 patent expands upon the Company's previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cellenriched fat grafts. Cytori Therapeutics' intellectual property portfolio currently includes 19 issued U.S. and international patents and 100 pending applications worldwide relating to the devices, methods and uses of adiposederived stem and regenerative cells.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forwardlooking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forwardlooking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
Cytori Therapeutics, Inc.
Cytori is an emerging leader in regenerative medicine, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications. www.cytori.com